Erasca Inc
ERAS
NASDAQ
Biotechnology
$18.38
USD
+0.52 (+2.91%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.25B
Volume 2.5M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-287.22M
TTM
-123.9%
YoY
Operating Cash Flow
$-98.02M
TTM
+1.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 9.5 | 10.1 | 9.4 | 10.6 | 11.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 38.1 | 34.5 | 32.6 | 187.9 | 47.6 |
Operating Income | -38.1 | -34.5 | -32.6 | -187.9 | -47.6 |
EBITDA | -37.3 | -33.8 | -31.9 | -187.2 | -46.9 |
Other Income / Expense | -0.1 | -0.0 | -0.1 | 0.0 | -0.1 |
Total Other Income / Expense | 4.2 | 3.9 | 3.5 | 4.5 | 3.5 |
Income Before Income Taxes | -33.9 | -30.6 | -29.1 | -183.4 | -44.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -33.9 | -30.6 | -29.1 | -183.4 | -44.1 |
Consolidated Net Income / Loss | -33.9 | -30.6 | -29.1 | -183.4 | -44.1 |
Net Income Attributable to Common Shareholders | -33.9 | -30.6 | -29.1 | -183.4 | -44.1 |
Basic EPS | -$0.12 | -$0.11 | -$0.10 | -$0.60 | -$0.14 |
Diluted EPS | -$0.12 | -$0.11 | -$0.10 | -$0.60 | -$0.14 |
Basic Shares Outstanding | 283.4M | 283.7M | 283.8M | 304.3M | 311.3M |
Diluted Shares Outstanding | 283.4M | 283.7M | 283.8M | 304.3M | 311.3M |